SCYNEXIS Inc
Company Profile
Business description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Contact
1 Evertrust Plaza
13th Floor
Jersey CityNJ07302 - 6548
USAT: +1 201 884-5485
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
29
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,796.80 | 29.60 | -0.34% |
| CAC 40 | 7,723.47 | 27.20 | 0.35% |
| DAX 40 | 24,073.67 | 286.22 | 1.20% |
| Dow JONES (US) | 44,406.36 | 422.17 | -0.94% |
| FTSE 100 | 8,806.53 | 16.38 | -0.19% |
| HKSE | 23,887.83 | 28.23 | -0.12% |
| NASDAQ | 20,412.52 | 188.59 | -0.92% |
| Nikkei 225 | 39,716.05 | 128.37 | 0.32% |
| NZX 50 Index | 12,710.12 | 54.83 | -0.43% |
| S&P 500 | 6,229.98 | 49.37 | -0.79% |
| S&P/ASX 200 | 8,561.00 | 28.30 | -0.33% |
| SSE Composite Index | 3,473.13 | 0.81 | 0.02% |